JonesResearch downgraded Korro Bio (KRRO) to Hold from Buy without a price target after the company announced KRRO-110 did not reach target levels of functional alpha-1 antitrypsin. The firm cites the stock’s lack of near-term catalysts and failure to demonstrate proof-of-concept for its RNA editing platform for the downgrade.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: